Yes — most men with a history of prostate cancer can qualify for life insurance, and early-stage, low-grade cases are often among the most favorably underwritten cancer histories in the entire industry. The Gleason score, PSA trend, and time since treatment are what carriers focus on most.
Prostate cancer is one of the most common cancer diagnoses in men, and because it’s frequently slow-growing and highly treatable, underwriters have well-developed, often lenient guidelines for evaluating it. Here’s what to expect.
How underwriters evaluate prostate cancer
Prostate cancer underwriting centers on three main factors: the Gleason score (which measures how aggressive the cancer cells appear), the stage at diagnosis, and how your PSA (prostate-specific antigen) has trended since treatment. Time since diagnosis and treatment also matters significantly — the longer your clean follow-up record, the better your outcome.
Because prostate cancer varies so widely in aggressiveness, from cases so slow-growing that doctors recommend active surveillance instead of treatment, to more aggressive forms requiring surgery or radiation, underwriters treat this diagnosis with more nuance than almost any other cancer type.
| Gleason Score / Grade | Typical Waiting Period | Likely Rate Class |
|---|---|---|
| Gleason 6 or below (low-grade) | 1–2 years disease-free | Standard to preferred |
| Gleason 7 (intermediate-grade) | 2–5 years disease-free | Standard, sometimes with mild rating |
| Gleason 8+ (high-grade) | 5+ years disease-free | Table-rated; carrier pool narrows |
These are general patterns — actual outcomes vary by carrier, PSA trend, and treatment type, which is exactly why comparing carriers matters for this diagnosis.
Why PSA monitoring matters so much
After prostate cancer treatment, PSA levels are tracked closely to detect any sign of recurrence. A stable, low, or undetectable PSA over multiple consecutive tests is one of the strongest positive signals you can bring to a life insurance application.
Underwriters typically want to see at least two to three consecutive PSA readings post-treatment showing stability before offering the best available rates. If your PSA has been rising — even slightly — carriers will want a clearer picture from your urologist before making a decision, and some may postpone the application until the trend is better understood.
How treatment type factors in
Prostate cancer treatment varies widely, and underwriters consider the approach as part of the overall picture.
Active surveillance. For very low-risk cases where doctors monitor the cancer rather than treat it immediately, some carriers view this favorably since it reflects a slow-growing, low-aggressiveness diagnosis. Others may want to see eventual treatment or a longer surveillance record before offering top rates.
Surgery (prostatectomy). A common and effective treatment. Clean margins and a stable post-surgical PSA support a favorable underwriting outcome.
Radiation therapy. Similarly effective, with a stable post-treatment PSA trend supporting standard or better rates over time.
Hormone therapy. Often used for higher-grade or recurrent cases. This is generally viewed as an indicator of more advanced disease and will typically result in a longer required waiting period and closer underwriting review.
What rates actually look like
A 60-year-old non-smoker with Gleason 6 prostate cancer, two years disease-free with a stable PSA, might qualify for standard or preferred rates at several carriers — a $500,000 15-year term policy in that scenario might run $140 to $190 per month depending on the carrier.
The same profile with a Gleason 8 diagnosis and a five-year disease-free record might see a table-rated premium in the $220 to $310 per month range for identical coverage.
The spread between carriers on prostate cancer cases can be significant, since different companies weigh Gleason score, PSA trend, and treatment type differently. This is where an independent broker makes a measurable difference — matching your specific diagnosis and monitoring history to the carrier most likely to offer the best outcome.
A real placement from our book
Client — age 63, Las Vegas, NV. A client came to us three years after a radical prostatectomy for Gleason 7 prostate cancer. His PSA had been undetectable at every check since surgery, and he had consistent urology follow-up documented throughout. He’d been quoted a heavy table rating by one national carrier that weighted the original Gleason score more heavily than his clean post-surgical PSA trend.
We pre-screened his case with three carriers known for placing more weight on post-treatment PSA stability than the original diagnosis alone. One approved him at standard non-tobacco rates for $500,000 of 15-year term at $172 per month, compared to the $265 per month he’d been quoted elsewhere — a savings of $16,740 over the life of the policy for identical coverage.
Frequently Asked Questions
Can you get life insurance after prostate cancer?
Yes. Most men with a history of prostate cancer can qualify for life insurance, particularly with a low Gleason score, a stable PSA trend, and time since treatment. Standard or even preferred rates are achievable for many early-stage cases.
What Gleason score is needed to get standard life insurance rates?
Gleason 6 or below is generally viewed most favorably and often qualifies for standard to preferred rates after a one-to-two year disease-free period. Higher Gleason scores are still insurable but typically require a longer waiting period.
Does PSA level affect my life insurance rate?
Yes. A stable or undetectable PSA over multiple consecutive tests after treatment is one of the strongest positive factors in a prostate cancer application. A rising PSA may result in a postponed decision.
How long after prostate cancer treatment can I apply for life insurance?
This depends on your Gleason score. Low-grade cases may be insurable after just one to two years disease-free, while higher-grade cases typically require five or more years of stability.
Is active surveillance for prostate cancer viewed the same as treatment?
Not always. Some carriers view active surveillance favorably since it reflects a low-risk diagnosis, while others prefer to see a longer surveillance record or completed treatment before offering top rates.
What helps your application
Get your PSA history organized. Have your urologist provide a summary of your PSA readings since diagnosis and treatment. A clear, stable trend is one of the most persuasive things you can bring to an application.
Document your Gleason score and treatment details. Carriers want specifics — original Gleason score, treatment type, and any pathology report details confirming clean margins if you had surgery.
Stay current with urology follow-up. Consistent monitoring signals to underwriters that any recurrence would be caught early.
Work with a broker who places prostate cancer cases regularly. Carrier guidelines vary enormously on how much weight they give the original diagnosis versus your post-treatment trend. The right match can mean the difference between a heavy rating and standard rates.
If you’re also working out how much coverage you need, our life insurance needs calculator is a good starting point.
Get your free quote today
At Term Insurance Brokers, prostate cancer cases are part of what we handle every week. We represent more than 30 top-rated carriers and know exactly which ones take the most favorable view of your specific Gleason score, treatment history, and PSA trend.
There’s no cost for a quote and no obligation. We do the carrier comparison — you make the decision.
Get Your Free Quote Today
No cost. No obligation. We shop 30+ carriers to find the right fit for you.
| Call 888-972-0024 | Get a Quote |
Term Insurance Brokers is an independent brokerage licensed in 35+ states, based in Las Vegas, Nevada. We are not affiliated with any single insurance company.